Table 1.
The approved CAR-T products for B-cell non-Hodgkin lymphoma
| Product | CAR construct | Year of approval | Indication | Bridging therapy | CAR-T dose | ORR | CR rate | Median PFS | Incidence of grade 3/4 CRS | Incidence of grade3/4 ICANS |
|---|---|---|---|---|---|---|---|---|---|---|
| Axicabtagene ciloleucel | CD19-CD28-CD3ζ | 2017 | Refractory LBCL | No | 2 × 10^6 cell/kg | 83% | 58% | 5.9 months (3.3 to 15.0) | 11% (12/108) | 32% |
| Tisagenlecleucel | CD19–4-1BB - CD3ζ | 2018 | Relapsed or refractory DLBCL in adults | Yes | (0.1–6) × 10^8 CAR-positive viable T cells | 52% | 40% | 8.3 months (5.8 to 11.7) | 22% | 12% |
| Brexucabtagene autoleucel | CD19-CD28-CD3ζ | 2020 | Relapsed or refractory MCL | Yes | 2 × 10^6 cell/kg | 85% | 59% | 4.8 months | 15% | 31% |
| Breyanzi (Lisocabtagene maraleucel) | CD19–4-1BB - CD3ζ | 2021 | Relapsed or refractory LBCL | Yes | 50 × 106, 100 × 106 and 150 × 106 CAR-positive T cells | 73% | 53% | NR | 2% (6/269) | 10% (27/269) |
Abbreviations: ORR objective response rate, CR complete response, PFS progression-free survival, CRS cytokine release syndrome, ICANS immune effector cell-associated neurotoxicity syndrome, LBCL large B-cell lymphoma, DLBCL diffuse large B-celllymphoma, MCL mantle-cell lymphoma